nanoQuinon

nanoQuinon is a nanoparticle-based oral formulation of ubidecarenone (Coenzyme Q10) developed to enhance the bioavailability of this lipophilic compound. It was investigated by Kompetenznetz Parkinson e.V. (Parkinson's Competence Network, Germany) in a Phase 2 clinical trial for the treatment of progressive supranuclear palsy (PSP), a rare and fatal neurodegenerative tauopathy. Ubidecarenone is a small molecule that acts as an essential cofactor in the mitochondrial electron transport chain, serving as the physiological electron recipient of Complex I and Complex II, and an electron donor for Complex III. By facilitating electron transfer, it supports ATP production via oxidative phosphorylation and functions as a potent antioxidant. The nanoQuinon formulation was specifically studied to determine if it could improve brain energy metabolism in PSP patients, addressing the mitochondrial dysfunction characteristic of the disease.

Brand names

nanoQuinon

Other names

ubidecarenoneCoenzyme Q10CoQ10CoQ-10CoQ 10ubiquinone